FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3189142708> ?p ?o ?g. }

• W3189142708 endingPage "e26711" @default.
• W3189142708 startingPage "e26711" @default.
• W3189142708 abstract "Growth hormone (GH) treatment is known to be effective in increasing stature in children with a short stature born small for gestational age (SGA). This multicentre, randomized, open-label, comparative, phase III study aimed to evaluate the efficacy and safety of Growtropin-II (recombinant human GH) and to demonstrate that the growth-promoting effect of Growtropin-II is not inferior to that of Genotropin in children with SGA (NCT ID: NCT02770157).Seventy five children who met the inclusion criteria were randomized into 3 groups in a ratio of 2:2:1 (the study group [Growtropin-II, n = 30], control group [Genotropin, n = 30], and 26-week non-treatment group [n = 15]). The study and control groups received subcutaneous injections of Growtropin-II and Genotropin, respectively for 52 weeks, whereas the non-treatment group underwent a non-treatment observation period during weeks 0 to 26 and a dosing period during weeks 27 to 52 and additional dosing till week 78 only in re-consenting children.No significant differences in demographic and baseline characteristics between the groups were observed. The mean ± standard deviation change difference in annualized height velocity (aHV) (study group - control group) was 0.65 ±2.12 cm/year (95% confidence interval [CI], -0.53 to 1.83), whereas the lower limit for the 2-sided 95% CI was -0.53 cm/year. Regarding safety, treatment-emergent adverse events (TEAEs) occurred in 53.33% children in the study group and 43.33% children in the control group; the difference in the incidence of TEAEs between the 2 treatment groups was not statistically significant (P = .4383). A total of 17 serious adverse events (SAEs) occurred in 13.33% children in the treatment groups, and no significant difference in incidence between groups (P = .7065) was seen. Two cases of adverse drug reaction (ADR) occurred in 2 children (3.33%): 1 ADR (injection site swelling or pain) occurred in 1 child (3.33%) each in the study and control groups.This study demonstrates that the change in aHV from the baseline till 52 weeks with Growtropin-II treatment is non-inferior to that with Genotropin treatment in children with short stature born SGA. Growtropin-II is well-tolerated, and its safety profile is comparable with that of Genotropin over a 1-year course of treatment." @default.
• W3189142708 created "2021-08-16" @default.
• W3189142708 creator A5014168443 @default.
• W3189142708 creator A5030006412 @default.
• W3189142708 creator A5031163211 @default.
• W3189142708 creator A5039350601 @default.
• W3189142708 creator A5042083758 @default.
• W3189142708 creator A5044020391 @default.
• W3189142708 creator A5048941690 @default.
• W3189142708 creator A5052219459 @default.
• W3189142708 creator A5052398257 @default.
• W3189142708 creator A5058498133 @default.
• W3189142708 creator A5058503965 @default.
• W3189142708 creator A5074434351 @default.
• W3189142708 creator A5084241485 @default.
• W3189142708 creator A5088475666 @default.
• W3189142708 date "2021-07-30" @default.
• W3189142708 modified "2023-10-14" @default.
• W3189142708 title "Efficacy and safety of the recombinant human growth hormone in short children born small for gestational age" @default.
• W3189142708 cites W1967606132 @default.
• W3189142708 cites W1990078422 @default.
• W3189142708 cites W2011927653 @default.
• W3189142708 cites W2024951997 @default.
• W3189142708 cites W2025091616 @default.
• W3189142708 cites W2029115786 @default.
• W3189142708 cites W2038215824 @default.
• W3189142708 cites W2094635868 @default.
• W3189142708 cites W2096601431 @default.
• W3189142708 cites W2122174849 @default.
• W3189142708 cites W2123493017 @default.
• W3189142708 cites W2124380228 @default.
• W3189142708 cites W2129317932 @default.
• W3189142708 cites W2147185790 @default.
• W3189142708 cites W2152371714 @default.
• W3189142708 cites W2777808577 @default.
• W3189142708 cites W2885467051 @default.
• W3189142708 cites W2888267005 @default.
• W3189142708 cites W2946348977 @default.
• W3189142708 cites W2972986139 @default.
• W3189142708 cites W963071500 @default.
• W3189142708 doi "https://doi.org/10.1097/md.0000000000026711" @default.
• W3189142708 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8322493" @default.
• W3189142708 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34397702" @default.
• W3189142708 hasPublicationYear "2021" @default.
• W3189142708 type Work @default.
• W3189142708 sameAs 3189142708 @default.
• W3189142708 citedByCount "1" @default.
• W3189142708 countsByYear W31891427082023 @default.
• W3189142708 crossrefType "journal-article" @default.
• W3189142708 hasAuthorship W3189142708A5014168443 @default.
• W3189142708 hasAuthorship W3189142708A5030006412 @default.
• W3189142708 hasAuthorship W3189142708A5031163211 @default.
• W3189142708 hasAuthorship W3189142708A5039350601 @default.
• W3189142708 hasAuthorship W3189142708A5042083758 @default.
• W3189142708 hasAuthorship W3189142708A5044020391 @default.
• W3189142708 hasAuthorship W3189142708A5048941690 @default.
• W3189142708 hasAuthorship W3189142708A5052219459 @default.
• W3189142708 hasAuthorship W3189142708A5052398257 @default.
• W3189142708 hasAuthorship W3189142708A5058498133 @default.
• W3189142708 hasAuthorship W3189142708A5058503965 @default.
• W3189142708 hasAuthorship W3189142708A5074434351 @default.
• W3189142708 hasAuthorship W3189142708A5084241485 @default.
• W3189142708 hasAuthorship W3189142708A5088475666 @default.
• W3189142708 hasBestOaLocation W31891427081 @default.
• W3189142708 hasConcept C120665830 @default.
• W3189142708 hasConcept C121332964 @default.
• W3189142708 hasConcept C126322002 @default.
• W3189142708 hasConcept C168563851 @default.
• W3189142708 hasConcept C187212893 @default.
• W3189142708 hasConcept C197934379 @default.
• W3189142708 hasConcept C2777288759 @default.
• W3189142708 hasConcept C2777871287 @default.
• W3189142708 hasConcept C2778376644 @default.
• W3189142708 hasConcept C2779234561 @default.
• W3189142708 hasConcept C2780938740 @default.
• W3189142708 hasConcept C44249647 @default.
• W3189142708 hasConcept C54355233 @default.
• W3189142708 hasConcept C61511704 @default.
• W3189142708 hasConcept C71924100 @default.
• W3189142708 hasConcept C86803240 @default.
• W3189142708 hasConceptScore W3189142708C120665830 @default.
• W3189142708 hasConceptScore W3189142708C121332964 @default.
• W3189142708 hasConceptScore W3189142708C126322002 @default.
• W3189142708 hasConceptScore W3189142708C168563851 @default.
• W3189142708 hasConceptScore W3189142708C187212893 @default.
• W3189142708 hasConceptScore W3189142708C197934379 @default.
• W3189142708 hasConceptScore W3189142708C2777288759 @default.
• W3189142708 hasConceptScore W3189142708C2777871287 @default.
• W3189142708 hasConceptScore W3189142708C2778376644 @default.
• W3189142708 hasConceptScore W3189142708C2779234561 @default.
• W3189142708 hasConceptScore W3189142708C2780938740 @default.
• W3189142708 hasConceptScore W3189142708C44249647 @default.
• W3189142708 hasConceptScore W3189142708C54355233 @default.
• W3189142708 hasConceptScore W3189142708C61511704 @default.
• W3189142708 hasConceptScore W3189142708C71924100 @default.
• W3189142708 hasConceptScore W3189142708C86803240 @default.
• W3189142708 hasIssue "30" @default.
• W3189142708 hasLocation W31891427081 @default.

• next